Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Gw Pharma ADR (GWPH)

Gw Pharma ADR (GWPH)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,198,967
  • Shares Outstanding, K 30,890
  • Annual Sales, $ 12,730 K
  • Annual Income, $ -295,160 K
  • 60-Month Beta 2.28
  • Price/Sales 248.51
  • Price/Cash Flow N/A
  • Price/Book 4.55

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.66
  • Number of Estimates 9
  • High Estimate -0.36
  • Low Estimate -1.56
  • Prior Year -2.35
  • Growth Rate Est. (year over year) +71.91%

Price Performance

See More
Period Period Low Period High Performance
1-Month
98.90 +0.31%
on 11/20/19
140.68 -29.48%
on 11/05/19
-18.90 (-16.00%)
since 10/18/19
3-Month
98.90 +0.31%
on 11/20/19
155.26 -36.10%
on 08/21/19
-51.64 (-34.23%)
since 08/20/19
52-Week
90.14 +10.06%
on 12/27/18
196.00 -49.38%
on 05/07/19
-22.00 (-18.15%)
since 11/20/18

Most Recent Stories

More News
New Records and New Milestones

New Records and New Milestones

FTNT : 102.45 (-2.49%)
PAYC : 260.93 (+8.95%)
VXX : 17.75 (+1.02%)
GWPH : 99.21 (-4.20%)
ASND : 117.60 (+3.65%)
TRWH : 22.57 (-0.57%)
VAPO : 10.51 (-3.84%)
Haemonetics (HAE) Grows on New Products, Robust Plasma Sales

Haemonetics (HAE) witnesses a steady uptick in Plasma franchise, fueled by favorable price, volume and mix.

EW : 244.23 (+0.28%)
NUVA : 71.48 (-1.43%)
GWPH : 99.21 (-4.20%)
HAE : 120.08 (-0.63%)
GW Pharmaceuticals, NetGear, Cisco Systems and NetApp highlighted as Zacks Bull and Bear of the Day

GW Pharmaceuticals, NetGear, Cisco Systems and NetApp highlighted as Zacks Bull and Bear of the Day

CSCO : 45.08 (-0.86%)
NTGR : 25.84 (-2.05%)
NTAP : 61.44 (-2.32%)
GWPH : 99.21 (-4.20%)
Here's Why You Should Hold on to CVS Health (CVS) For Now

Investors can still hold on to CVS Health (CVS) stock, thanks to its solid prospects.

NUVA : 71.48 (-1.43%)
HAE : 120.08 (-0.63%)
GWPH : 99.21 (-4.20%)
CVS : 74.92 (-0.57%)
CVS Health's New Plans With Aetna May Improve Health Outcomes

CVS Health's (CVS) Health Care Benefits segment develops Medicare program with Aetna.

NUVA : 71.48 (-1.43%)
HAE : 120.08 (-0.63%)
GWPH : 99.21 (-4.20%)
CVS : 74.92 (-0.57%)
Bull of the Day: GW Pharmaceuticals (GWPH)

Bull of the Day: GW Pharmaceuticals (GWPH)

GWPH : 99.21 (-4.20%)
Syneos Health Collaborates with AiCure for Patient Engagement

Syneos Health (SYNH) aims to optimize patient engagement and trial success by partnering with AiCure.

HAE : 120.08 (-0.63%)
NUVA : 71.48 (-1.43%)
GWPH : 99.21 (-4.20%)
SYNH : 52.08 (+0.81%)
Here's Why You Should Add NuVasive (NUVA) to Your Portfolio

Investors continue to be optimistic about NuVasive's (NUVA) stellar performance.

HAE : 120.08 (-0.63%)
GWPH : 99.21 (-4.20%)
MDT : 111.79 (+0.65%)
NUVA : 71.48 (-1.43%)
Insulet Rides on Omnipod's Wider Market Reach, New Products

Insulet (PODD) achieves several milestones with respect to strengthening Omnipod's market access.

GWPH : 99.21 (-4.20%)
NUVA : 71.48 (-1.43%)
HAE : 120.08 (-0.63%)
PODD : 180.23 (-0.36%)
Hologic's (HOLX) 3DQuorum Imaging Technology Gets FDA Nod

The regulatory clearance is likely to boost Hologic's (HOLX) Breast and Skeletal Health Solutions business segment.

HOLX : 49.19 (+4.33%)
HAE : 120.08 (-0.63%)
NUVA : 71.48 (-1.43%)
GWPH : 99.21 (-4.20%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell and ranks in the Top 1% of all short term signal directions.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Trade GWPH with:

Business Summary

GW Pharmaceuticals plc is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The Company's lead product, Sativex is used for the treatment of MS symptoms, cancer pain, and...

See More

Key Turning Points

2nd Resistance Point 107.08
1st Resistance Point 103.15
Last Price 99.21
1st Support Level 97.09
2nd Support Level 94.96

See More

52-Week High 196.00
Fibonacci 61.8% 155.56
Fibonacci 50% 143.07
Fibonacci 38.2% 130.58
Last Price 99.21
52-Week Low 90.14

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar